[Skip to Content]
[Skip to Content Landing]
Article
February 15, 1980

A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial Infarction

Author Affiliations

From the Aspirin Myocardial Infarction Study Research Group. Sponsored by the National Heart, Lung, and Blood Institute, Bethesda, Md.

JAMA. 1980;243(7):661-669. doi:10.1001/jama.1980.03300330019023
Abstract

The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung, and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. Cause-specific mortality, nonfatal events, and side effects were also evaluated. Over a 13-month period, 4,524 persons between the ages of 30 and 69 years were randomized to either 1 g of aspirin per day (2,267 persons) or placebo (2,257 persons). High levels of patient compliance to study protocol were indicated by various measures. Total mortality during the entire follow-up period was 10.8% in the aspirin group and 9.7% in the placebo group. Three-year total mortality was 9.6% in the aspirin group and 8.8% in the placebo group. The percentage of definite nonfatal MI was 8.1% in the placebo group and 6.3% in the aspirin group. Coronary incidence (coronary heart disease mortality or definite nonfatal MI) was 14.1% in the aspirin group and 14.8% in the placebo group. Symptoms suggestive of peptic ulcer, gastritis, or erosion of gastric mucosa occurred in 23.7% of the aspirin group and 14.9% in the placebo group. Based on AMIS results, aspirin is not recommended for routine use in patients who have survived an MI.

(JAMA 243:661-669, 1980)

×